New Chemical Entities Entering Phase III Trials in 2011

被引：3

作者：

Notte, Gregory T. ^{[1
]}

机构：

[1] Gilead Sci Inc, San Mateo, CA USA

来源：

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 47 | 2012年 / 47卷

关键词：

HEPATITIS-C VIRUS; RECEPTOR AGONIST; DISCOVERY; INHIBITOR; POTENT; SERIES; ANTAGONISTS; DESIGN; OPTIMIZATION; DISEASE;

D O I：

10.1016/B978-0-12-396492-2.00030-8

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：477 / 498

页数：22

共 50 条

[1] New Chemical Entities Entering Phase III Trials in 2012
Notte, Gregory T.
[J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 48, 2013, 48 : 451 - 469
[2] New Chemical Entities Entering Phase III Trials in 2013
Notte, Gregory T.
[J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 417 - 436
[3] Targeting population entering phase III trials: A new stratified adaptive phase II design
Tournoux-Facon, Caroline
De Rycke, Yann
Tubert-Bitter, Pascale
[J]. STATISTICS IN MEDICINE, 2011, 30 (08) : 801 - 811
[4] Methodological considerations in the design of trials for safety assessment of new drugs and chemical entities
Cornel Pater
[J]. Current Controlled Trials in Cardiovascular Medicine, 2005, 6
[5] SUCCESS RATES FOR NEW CHEMICAL ENTITIES (NCES) ENTERING CLINICAL-TESTING IN THE UNITED-STATES
DIMASI, JA
BRYANT, NR
LASAGNA, L
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (02) : 191 - 191
[6] Methodological considerations in the design of trials for safety assessment of new drugs and chemical entities
Pater, C
[J]. CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2005, 6 (1):
[7] ENTERING A NEW PHASE
RYAN, B
[J]. BYTE, 1990, 15 (12): : 289 - &
[8] Results of phase II and phase III trials with new aromatase inhibitors
Jonat, W
[J]. BREAST, 1996, 5 (03): : 209 - 215
[9] ENTERING UPON A NEW PHASE
HOSSNER, R
[J]. ATOMWIRTSCHAFT-ATOMTECHNIK, 1991, 36 (11): : 493 - 493
[10] NERVA - ENTERING A NEW PHASE
SCHROEDER, RW
[J]. ASTRONAUTICS & AERONAUTICS, 1968, 6 (05): : 42 - +